http://www.bloomberg.com/news/articles/2016-10-09/bristol-myers-lung-cancer-drug-disappoints-in-patient-trial
http://www.gulf-times.com/story/516755/Merck-s-drug-succeeds-in-lung-cancer-test-could-be
http://www.webbreakingnews.com/2016/10/09/merck-co-mrk-stake-held-by-whitnell-co.html
http://www.finanznachrichten.de/nachrichten-2016-10/38803197-pfizer-presents-promising-new-immunotherapy-combination-data-with-inlyta-axitinib-in-advanced-renal-cell-carcinoma-rcc-004.htm

http://www.finanzen.net/nachricht/aktien/Pfizer-Presents-Promising-New-Immunotherapy-Combination-Data-With-INLYTA-axitinib-In-Advanced-Renal-Cell-Carcinoma-RCC-5124168
http://www.khaleejtimes.com/lifestyle/health-fitness/new-day-in-lung-cancer-as-merck-drug-shines-works-with-chemo
http://indianexpress.com/article/lifestyle/health/new-clinical-data-shows-benefits-in-untreated-lung-cancer-patients-as-merck-drug-shines-3073688/
http://in.reuters.com/article/health-cancer-merck-co-idINKCN1290A3
http://news.trust.org/item/20161009091753-2npws/
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-Study-May-Boost-Use-of-Merck-Lung-Cancer-Drug-23186479/


http://www.marketwatch.com/story/two-major-studies-to-be-presented-at-esmo-2016-congress-presidential-symposium-demonstrate-potential-of-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-in-a-broad-range-of-patients-2016-10-09
http://www.marketwatch.com/story/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-data-to-be-presented-at-esmo-2016-congress-2016-10-09
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-KEYTRUDA-pembrolizumab-Showed-Continued-Overall-Survival-Benefit-Compared-to-Chemotherapy-23186461/
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-Two-Major-Studies-to-Be-Presented-at-ESMO-2016-Congress-Presidential-Symposium-Demonstrate-P-23186466/
http://www.dailymail.co.uk/~/article-3829054/index.html
http://www.webbreakingnews.com/2016/10/09/q3-2016-eps-estimates-for-merck-co-mrk-raised-by-analyst.html
http://www.dailypolitical.com/2016/10/08/sigma-planning-corp-acquires-2704-shares-of-merck-co-mrk.html
http://www.dailypolitical.com/2016/10/08/los-angeles-capital-management-equity-research-inc-has-142039000-position-in-merck-co-mrk.html

http://www.finanznachrichten.de/nachrichten-2016-10/38801457-merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presen-004.htm
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-Announces-Longer-Term-Follow-Up-of-Overall-Survival-Data-for-KEYTRUDA-pembrolizumab-in-Pa-23184265/

http://www.marketwatch.com/story/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients-2016-10-08
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-New-KEYTRUDA-pembrolizumab-Data-in-Advanced-Urothelial-Cancer-Demonstrate-Overall-Respons-23183896/
http://www.arabnews.com/node/995906/world
http://news.kuwaittimes.net/website/new-day-lung-cancer-merck-drug-shines-keytruda-cuts-risk-death-40-big-lung-cancer-study/
http://www.irishtimes.com/business/health-pharma/lung-cancer-drug-fails-to-show-advantage-in-clinical-trial-1.2822908
http://timesofoman.com/article/93865/World/Europe/As-a-monotherapy-Keytruda-halved-the-risk-of-disease-progression-and-cut-overall-deaths-by-40-per-ce
http://www.marketwired.com/press-release/dynavax-presents-early-clinical-data-from-lead-cancer-immunotherapy-candidate-sd-101-nasdaq-dvax-2165023.htm
http://www.4-traders.com//DYNAVAX-TECHNOLOGIES-CORP-19120561/news/Dynavax-Technologies-Presents-Early-Clinical-Data-From-Lead-Cancer-Immunotherapy-Candidate-SD-101-23186919/
http://www.finanznachrichten.de/nachrichten-2016-10/38802845-dynavax-presents-early-clinical-data-from-lead-cancer-immunotherapy-candidate-sd-101-at-esmo-annual-congress-sd-101-in-combination-with-pembrolizu-256.htm
http://www.timesofmalta.com/articles/view/20161009/health-fitness/new-day-for-lung-cancer-treatment-as-drug-shines-in-trials.627485
https://in.news.yahoo.com/day-lung-cancer-merck-drug-shines-works-chemo-094216005--finance.html
http://www.bloomberg.com/news/articles/2016-10-09/roche-s-tecentriq-extends-lung-cancer-patients-lives-in-study-iu28jggl
https://www.ft.com/content/8352f838-8ccf-11e6-8aa5-f79f5696c731
http://nation.com.pk/blogs/10-Oct-2016/cost-of-living-life-saving-drug-goes-from-1-to-750-a-pill
http://www.bloomberg.com/news/articles/2016-10-09/astrazeneca-rivals-take-aim-at-lung-cancer-with-combo-therapies
http://www.zawya.com/story/ADIB_launches_further_100_capitalprotected_equity_investment-ZAWYA20161009045727/
http://www.dailymail.co.uk/~/article-3828484/index.html
http://www.wgmd.com/better-buy-exelixis-inc-vs-roche/
http://www.fool.com/investing/2016/10/08/better-buy-exelixis-inc-vs-roche.aspx?source=eptfxblnk0000004&utm_campaign=article&utm_medium=feed&utm_source=foxbusiness
http://www.fool.com/investing/2016/10/08/better-buy-exelixis-inc-vs-roche.aspx
http://www.emailwire.com/release/281938-Glaucoma-Treatment-Market-Trends-Opportunities-And-Analysis.html
http://irishamerica.com/2016/10/irish-america-celebrates-3rd-annual-healthcare-life-sciences-50/
http://arstechnica.com/science/2016/10/for-ripping-off-medicaid-epipen-maker-mylan-pays-feds-465-million/
http://www.koreaherald.com/view.php?ud=20161009000303
http://www.benzinga.com/general/biotech/16/10/8535229/exclusive-interview-with-delmar-pharmaceutical-ceo-jeffrey-bacha
http://www.emailwire.com/release/281932-MO-Source-Industry-Professional-Survey-Growth-Size-Shares-Forecast-Analysis-and-Supply-Demand-to-2021.html
